Difference between NASH and NAFLD
NAFLD vs NASH difference spectrum 2024 2025
"NAFLD" AND "NASH" AND "MASLD" nomenclature
NAFLD vs NASH
The Relationship: Spectrum, Not Two Separate Diseases
NAFLD (umbrella) → Simple Steatosis (benign) → NASH (active injury) → Fibrosis → Cirrhosis → HCC
Side-by-Side Comparison
| Feature | NAFLD (Simple Steatosis) | NASH |
|---|---|---|
| Definition | Fat accumulation (>5% of hepatocytes) with no significant alcohol use | Fat + inflammation + hepatocyte injury (ballooning) |
| Histology | Steatosis only | Steatosis + lobular inflammation + hepatocellular ballooning (± fibrosis) |
| Liver injury markers | Usually normal or mildly elevated transaminases | Elevated ALT/AST (AST:ALT ratio typically <1) |
| Symptoms | Typically asymptomatic | Often asymptomatic, but may have fatigue, malaise, RUQ discomfort |
| Fibrosis risk | Very low progression risk | Can progress to fibrosis, cirrhosis, and HCC |
| Diagnosis | Imaging (ultrasound, MRI) or incidental lab finding | Requires liver biopsy for definitive diagnosis |
| Prognosis | Generally benign; may regress | Potentially serious; can lead to end-stage liver disease |
Pathogenesis: Why NASH is Worse
- Inflammasome activation in hepatocytes - releases pro-inflammatory cytokine IL-1
- Increased reactive oxygen species (ROS) production
- ER stress and mitochondrial dysfunction
- Lipotoxicity from specific lipid metabolites
- Gut microbiome dysbiosis - increased gut-derived endotoxins drive hepatic inflammation
- Hepatocyte injury then activates stellate cells, leading to collagen deposition and fibrosis
Risk Factors (shared by both)
- Type 2 diabetes / family history
- Obesity (especially central/visceral)
- Dyslipidemia (high triglycerides, low HDL, high LDL)
- Hypertension / metabolic syndrome
Diagnosis: The Key Practical Difference
- NAFLD can be diagnosed with imaging (hepatic steatosis on ultrasound/MRI) + exclusion of alcohol and other causes.
- NASH requires a liver biopsy to confirm the combination of steatosis, lobular inflammation, and hepatocyte ballooning. No blood test or imaging alone can reliably distinguish simple steatosis from NASH.
Important Naming Update (2023 onward)
- NAFLD is being replaced by MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease)
- NASH is being replaced by MASH (Metabolic dysfunction-Associated SteatoHepatitis)
Clinical Significance
- NAFLD (simple steatosis) carries a low but non-zero risk of progression - roughly 10-20% of patients progress to NASH over time.
- NASH is a leading and growing indication for liver transplantation in the US, and is set to overtake HCV as the primary driver of hepatocellular carcinoma.
- Patients with NAFLD also have an increased risk of coronary artery disease due to shared metabolic risk factors.
- Treatment for both: weight reduction, exercise, diet, and reversal of insulin resistance. Bariatric surgery is an option in selected cases. Drug therapies specifically targeting MASH (e.g., resmetirom/Rezdiffra) have received FDA approval.
Give you give me the difference of the two table you have above in a image form so that I can download that
A clean, professional medical comparison table titled "NAFLD vs NASH" with two columns side by side. The table has the following rows comparing NAFLD (Simple Steatosis) on the left and NASH (Nonalcoholic Steatohepatitis) on the right: Row 1 - Definition: NAFLD: "Fat accumulation (>5% of hepatocytes), no significant alcohol use" | NASH: "Fat + Inflammation + Hepatocyte injury (ballooning)" Row 2 - Histology: NAFLD: "Steatosis only" | NASH: "Steatosis + lobular inflammation + hepatocyte ballooning ± fibrosis" Row 3 - Liver Enzymes: NAFLD: "Normal or mildly elevated" | NASH: "Elevated ALT/AST (AST:ALT ratio <1)" Row 4 - Symptoms: NAFLD: "Typically asymptomatic" | NASH: "Often asymptomatic; may have fatigue, malaise, RUQ discomfort" Row 5 - Fibrosis Risk: NAFLD: "Very low" | NASH: "Can progress to fibrosis, cirrhosis, HCC" Row 6 - Diagnosis: NAFLD: "Imaging (ultrasound/MRI) + exclusion of other causes" | NASH: "Liver biopsy required" Row 7 - Prognosis: NAFLD: "Generally benign; may regress" | NASH: "Potentially serious; may lead to end-stage liver disease" Row 8 - Treatment: NAFLD: "Weight loss, diet, exercise" | NASH: "Weight loss, diet, exercise + pharmacotherapy (e.g. MASH-targeted drugs)" Row 9 - New Name (2023+): NAFLD: "MASLD" | NASH: "MASH" Use a medical/clinical color scheme: deep blue header for NAFLD column, deep orange/red header for NASH column, alternating light grey and white row backgrounds, bold row labels in dark grey on the left. Include a small note at the bottom: "NAFLD is the umbrella term; NASH is the advanced, inflammatory stage within the NAFLD spectrum." Clean sans-serif font, high contrast, easy to read.
Give me the spectrum of disease
A detailed medical diagram showing the full spectrum of NAFLD/MASLD disease progression as a horizontal left-to-right flowchart with arrows connecting each stage. Title at top: "NAFLD/MASLD: Spectrum of Disease" Stages from left to right: Stage 1 - "Normal Liver": healthy liver icon, light pink color, description "No fat accumulation, normal histology" Arrow pointing right → Stage 2 - "Simple Steatosis (NAFLD/MASLD)": yellow/gold color, description "Fat >5% of hepatocytes, No inflammation, No fibrosis, Reversible" Arrow pointing right → (labeled "10-20% progress") Stage 3 - "NASH / MASH": orange color, description "Steatosis + Lobular inflammation + Hepatocyte ballooning, ± early fibrosis (F1-F2)" Arrow pointing right → (labeled "progressive fibrosis") Stage 4 - "Advanced Fibrosis (F3)": dark orange/red, description "Bridging fibrosis, Stellate cell activation, Portal hypertension risk" Arrow pointing right → Stage 5 - "Cirrhosis (F4)": deep red, description "Nodular liver, Portal hypertension, Synthetic dysfunction, MELD score rises" Arrow pointing right → Stage 6 - "End-Stage Liver Disease / HCC": dark maroon/brown, description "Liver failure, Hepatocellular carcinoma, Liver transplant needed" Below the main flow, add a wide banner at the bottom showing the metabolic risk factors that drive the entire spectrum: "Underlying Drivers: Obesity • Insulin Resistance • Type 2 Diabetes • Dyslipidemia • Metabolic Syndrome" Also add a small reverse arrow under stages 1-3 labeled "Reversible with weight loss & lifestyle changes" Use clean medical illustration style, sans-serif font, bright professional colors, white background, clear labels. Include the new nomenclature in parentheses: NAFLD = MASLD, NASH = MASH.
- Normal Liver - baseline, no fat accumulation
- Simple Steatosis (NAFLD/MASLD) - fat only, no injury, largely reversible
- NASH/MASH - fat + inflammation + hepatocyte ballooning; the critical inflection point
- Advanced Fibrosis (F3) - bridging fibrosis, rising portal hypertension risk
- Cirrhosis (F4) - structural liver remodeling, nodular architecture
- End-Stage / HCC - liver failure or hepatocellular carcinoma, transplant territory
- Only about 10-20% of people with simple steatosis progress to NASH
- Progression is not always linear - some patients develop HCC even without full cirrhosis in NASH
- Stages 1-3 are potentially reversible with weight loss (even 7-10% body weight loss significantly reduces liver fat and inflammation)
- The entire spectrum is driven by the same metabolic substrate: insulin resistance, obesity, and dyslipidemia